Abstract:Yunbin Yang, Jinou Chen, Liangli Liu, Ling Li, Rui Yang, Kunyun Lu, Yubing Qiu, Xing Yang, Lin Xu Division of Tuberculosis Control and Prevention, Yunnan Center for Disease Control and Prevention, Kunming, People's Republic of China Correspondence: Lin Xu, Email Objective: Treating and managing rifampicin resistant tuberculosis (RR-TB) patients in Yunnan, China, are major challenges. This study aims to evaluate the risk of poor treatment outcomes in RR-TB patients, allowing clinical doctors to proactively target patients who would benefit from enhanced patient management. Methods: Four RR-TB care facilities in different regions of Yunnan province as the data collection points were selected. A total of 524 RR-TB patients were included in this study and randomly assigned into a training set (n=366) and a validation set (n=158). In the training set, four significant factors were screened by using a random forest model and a Lasso regression model, and then included in a logistic regression model to construct a nomogram for internal validation. Results: The successful treatment rate of RR-TB patients in training set was 42.6% (156/366), and the main poor treatment outcomes were loss to follow-up (66.7%) and death (18.1%). Low hemoglobin (HGB) (OR=0.977, 95% CI: 0.964– 0.989), long-regime (OR=2.784, 95% CI: 1.634– 4.842), poor culture results at the end of the 6th month (CR6TM) (OR=11.193, 95% CI: 6.507– 20.028), pre-extensively drug-resistant tuberculosis (pre-XDR) (OR=3.736, 95% CI: 1.294– 12.034) were risk factors for poor treatment outcomes in RR-TB patients. The Area Under Curve (AUC) of this model was 0.829 (95% CI: 0.787– 0.870), and there was good consistency between the predicted probability and the actual probability. The DCA curve showed that when the threshold probability was 20– 98%, the use of nomogram to predict the net benefit of poor treatment outcomes risk in RR-TB patients was higher. Conclusion: We combined multiple models to develop a nomogram for predicting poor treatment outcomes in RR-TB patients. This would help clinical doctors identify high-risk populations and enable them to proactively target RR-TB patients who will benefit from strengthened patient management. Keywords: drug resistance tuberculosis, poor treatment outcomes, prediction, model, nomogram Rifampicin resistant tuberculosis (RR-TB) is characterized by challenging diagnosis, long treatment duration, high treatment costs, more adverse reactions, and a high loss rate. 1,2 According to the World Health Organization (WHO), in China, there were approximately 30,000 RR-TB patients, accounting for 7.3% of the global total. In 2020, the successful treatment rate of RR-TB patients undergoing treatment was only 51%. 3 Ethiopian studies showed that 38–92% of TB patients reported income loss and 26–76% of TB patients lost their jobs due to unfavorable outcomes of RR-TB, further worsening the financial problem. 4 Yunnan, situated on China's southwestern border, is an economically underdeveloped province comprising 16 prefectures and 129 counties. The successful treatment rate for RR-TB patients in Yunnan was only about 50%~60%, with nearly 40%~50% of RR-TB patients experiencing poor treatment outcomes for various reasons, resulting in the continued spread of drug-resistant bacteria throughout the community. 5,6 Therefore, it is essential to analyze the factors associated with poor treatment outcome in RR-TB patients to prioritize intervention to improve outcomes among RR-TB patients with elevated risks. Many risk factors associated with unsuccessful treat ment outcomes of RR-TB had been reported, including older age, baseline alcohol use, cavitary disease, culture-positive at baseline, relapsed TB, treatment non-compliance, previous TB treatment, longer treatment duration and history of second-line drug resistance. 7–9 The clinical characteristic data that clinicians pay more attention to were less included in previous studies. At the same time, the clinical data were collected from only one facility would inevitably lead to the unrepresentativeness and unrepeatability of the analysis results. In addition, when many variables with highly linear correlation were collected, only using logistic regression model was easy to cause equation over fitting, and the included variables needed to be controlled and limited. Considering the above factors, this study included the multi-dimensional data of multiple RR-TB care facilities in Yunnan, and applied multiple statistical models to screen and control variable for the construction of influencing factor models, aiming to evaluate the risk of poor treatment outcomes in RR-TB patients in Yunnan, allowing clinical doctors to proactively target patients who would -Abstract Truncated-

Applying a Combined Model to Evaluate the Risk of Poor Treatment Outcomes in Rifampicin Resistant Tuberculosis Patients: A Multicenter Retrospective Study

Treatment Outcomes and Associated Influencing Factors Among Patients with Rifampicin-Resistant Tuberculosis: A Multicenter, Retrospective, Cohort Study in China

Changing trend analysis on early detection of rifampicin resistant tuberculosis patients in southwestern area of China, 2016–2020

A Scoring System Based on Laboratory Parameters and Clinical Features to Predict Unfavorable Treatment Outcomes in Multidrug- and Rifampicin-Resistant Tuberculosis Patients.

Risk factors and treatment outcomes of rifampicin-resistant tuberculosis in Guizhou Province from 2014 to 2018

Longitudinal Analysis of Prevalence and Risk Factors of Rifampicin-Resistant Tuberculosis in Zhejiang, China

Influencing Factors of Treatment Outcomes Among Patients with Pulmonary Tuberculosis: A Structural Equation Model Approach

Treatment Outcome of MDR/RR TB in a Resource-Constrained Setup: A Four-Year Retrospective Analysis

Clinical Characteristics and Outcome Predictors in Drug-Resistant Tuberculosis: A Comprehensive Analysis

Investigation for prognosis of hospitalized patients with pulmonary tuberculosis and analysis for related factors

Treatment Quality and Outcome for Multidrug-Resistant Tuberculosis Patients in Four Regions of China: a Cohort Study.

Assessment of Factors Associated with Unfavorable Outcomes among Drug-Resistant TB Patients: A 6-Year Retrospective Study from Pakistan.

Treatment outcomes and associated factors among patients with multidrug-resistant tuberculosis in Southwestern Oromia, Ethiopia: ten-year retrospective analysis

Affecting Factors Unfavorable Treatment Outcomes of Rifampicin-resistant/Multidrug-resistant Tuberculosis Patients Treated with Long-term Regimen

Treatment outcomes of the standardized regimens for patients with multidrug-resistant pulmonary tuberculosis in Wenzhou during 2013 to 2015

The survival analysis of rifampicin/multidrug-resistant tuberculosis patients based on the levels of inflammatory biomarkers: a retrospective cohort study

Incidence, Outcomes, and Risk Factors for Isoniazid-Resistant Tuberculosis from 2012 to 2022 in Eastern China

Impact of Genotypic and Phenotypic Resistance to Second-Line Anti-Tuberculosis Drugs on Treatment Outcomes in Multidrug-Resistant Tuberculosis in China.

Treatment cascade for patients with multidrug- or rifampicin-resistant tuberculosis and associated factors with patient attrition in southeastern China: a retrospective cohort study

The Mutational Signatures of Poor Treatment Outcomes on the Drug-Susceptiblemycobacterium Tuberculosisgenome

Risk factors analysis on anti-TB treatment outcomes of 757 primary pulmonary tuberculosis cases